Friday, July 31, 2026

HomeHealth NewsRadioligand therapy for HER2-positive cancers enters human trials for the first time

Radioligand therapy for HER2-positive cancers enters human trials for the first time

- Advertisement -

Credit: Pixabay/CC0 Public Domain

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial evaluating a novel radioligand therapy for HER2-positive cancers, including certain types of breast cancer.

Click here to view the original article.

- Advertisment -
- Advertisement -

Recently Viewed